Providence Cancer Institute Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2004
NCT00150657
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Providence Cancer Institute | Rachel Sanborn